Tooth Sensitivity Clinical Trial
Official title:
Preemptive Use of Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching: Randomized, Triple-blind, Controlled Clinical Trial
Objectives: This study aims to evaluate the effectiveness of preemptive administration of
non-steroidal anti-inflammatory Piroxicam-beta-Cyclodextrin on risk and level of tooth
sensitivity caused by in-office bleaching procedures using 35% hydrogen peroxide.
Fifty patients will be selected for this triple-blind, randomized, cross-over,
placebo-controlled clinical trial. Piroxicam-beta-Cyclodextrin (200 mg) or placebo will be
administrated in a single-dose thirty minutes prior to bleaching procedure. The whitening
treatment with 35% hydrogen peroxide will be carried out in two sessions with a 7-day
interval. Tooth sensitivity will be assessed Immediately before bleaching agent removal and
up to 24 hours after each session the procedure using analog visual and verbal scales. Color
alteration will be assessed by a bleach guide scale 7 days after each session. Relative risk
to sensitivity will be calculated and adjusted by session; while comparison of overall risk
will performed by Fisher's exact test. Data on the sensitivity level for both scales and
color shade will be subjected to the Mann-Whitney and Friedman tests, respectively (α =
0.05).
Methods & Materials:
This clinical trial was approved by the Scientific Review Committee and by the Ethics
Committee on Research Involving Humans at the University Hospital of the Federal University
of Sergipe (CAAE 50511415.1.0000.5546).
Trial design:
This study will be a randomized, triple-blind, placebo-controlled clinical trial with a
cross-over design. The patients included will be submitted to two in-office bleaching
sessions receiving placebo (control) or Piroxicam-beta-Cyclodextrin prior to the bleaching
procedure; while different treatments will be allocated for each session. A delay of 1 week
between the sessions (wash-out) will be established. The study will be conducted at the
clinic of the School of Dentistry of the local university from December 2016 to May 2017.
Participants:
Patients included in this clinical trial will be at least 18 years old with good oral health.
Patients with any of the six upper anterior teeth with caries lesions, restoration, severe
discoloration (e.g., stains caused by tetracycline), fluorosis, gingival recession, dentin
exposure, periodontal diseases, pulpitis, or endodontics treatment will be excluded.
Participants submitted to previous bleaching procedures, presenting prior tooth sensitivity,
known allergy to any component of medication used in the study, Continuous use of drugs with
anti-inflammatory actions, pregnant or breastfeeding will be also excluded. Only patients
presenting all six upper anterior teeth with shade mismatching with 2.5 M2 (Vita Bleachguide
3D-Master scale, Vita-Zahnfabrik, Bad Sackingen, Germany) or darker will be included.
Sample Size Calculation:
The sample calculation will be based on the primary binary outcome (sensitivity risk 24 hours
after the procedure) for superiority trial. Power of the test will be set at 80%, considering
a type I error of 0.05; risk to tooth sensitivity of 90%, based on a prior study using
similar bleaching agent, while a reduction around 30% with the treatment will be expected.
The calculation resulted in fifty patients.
Randomization:
A randomized list will be computer-generated by a person not involved in intervention or
evaluation. The participants were defined as blocks in the randomization process, where the
sequence of treatment (placebo or piroxicam-beta-cyclodextrin) will be randomly set for each
block by using computer-generated tables (www.sealedenvelope.com). The sequence will be
inserted into sealed envelopes numbered from 1 to 50 that were opened by the operator only at
the moment of the intervention. The patients were numbered according to the sequence of
enrollment. Neither the participant nor the operator knew the group allocation determining
blinding to the protocol.
Baseline evaluation:
Prior to bleaching procedure, the teeth will be cleaned using rubber cups associated to
pumice and water. The shades of six upper anterior teeth will be assessed on a baseline using
the bleach guide scale (Vita Bleach Guide,Vita-Zahnfabrik, Bad Säckinge, Germany). The
shades' tabs selected will be converted to scores ranging from 1 (whiter shade - 0M1) to 15
(darker shade - 5M3).
Intervention:
Thirty minutes prior to each bleaching session, the patients will receive a capsule
containing 20mg of piroxicam-beta-cyclodextrin or 20mg of placebo (inert content), according
to the randomization, while the capsules will present the same appearance. The capsules with
similar presentation will be manufactured by a person not involved in intervention or
evaluation and will be placed into two bottles identified by letters according to treatment.
Neither the operators responsible for intervention and evaluation nor the patients knew the
content of each capsule.
A light-cured resin dam will be applied (Top Dam, FGM, Joinville, SC, Brazil) on the gingival
tissue corresponding to the teeth to be bleached. A 35% hydrogen peroxide based bleaching
agent (Whiteness HP Maxx, FGM, Joinville, SC, Brazil) will be mixed and applied on the
vestibular surface of teeth, remaining for 45 minutes. After this time, the bleaching agent
will be removed. A second session will beas carried out after 1 week following the same
procedures. At this time, the patient received a single-dose capsule containing
piroxicam-beta-cyclodextrin or placebo (different from the ones received at first session)
thirty minutes before the procedure.
Evaluations:
The tooth sensitivity reported by patients will be recorded using both VAS and a verbal
rating (VRS) scales. For VAS, the patient set her/his sensitivity level by pointing with a
pen to the colored 10-cm scale and the distance from the border corresponding to absence of
pain will be recorded. Tooth sensitivity will be also scored according to VRS, where 0 =
none, 1 = mild, 2 = moderate, 3 = considerable, and 4 = severe.
The maximum level of tooth sensitivity will be evaluated during the bleaching procedure,
during the first 24 hours and the level of sensitivity at that time. VRS will define the
presence (score different from 0) or absence of tooth sensitivity in all time assessments.
One week after each session the tooth color will be evaluated again using the same procedure
described previously.
Statistical Analysis:
The demographic data from patients will be analyzed to determine age and gender for each
allocation sequence. Comparisons between the allocation sequences will be performed by the
Mann-Whitney test (age) and Fisher's exact (gender).
Based on presence of any tooth sensitivity (scores different from 0 for VRS), the absolute
risk, odds ratio and relative risk will be calculated regarding the treatments for each
moment of evaluation/session of bleaching, as well as its confidence intervals (95%). For
each moment, differences on presence/absence ratios will be analyzed by Fisher's exact test.
For the overall risk related to each treatment, the odds ratio will be adjusted to
independent variable "session of bleaching" using the Mantel-Haenszel statistic. The
homogeneity of odds ratios will be analyzed by the Breslow-Day and Tarone's tests. Following,
the odds ratio estimated will be converted to relative risk and the overall presence/absence
ratios will be analyzed by the McNemar's test, considering the study design (cross-over).
For VRS, the data from scores observed in each time of evaluation/session of bleaching will
be submitted to the Mann-Whitney rank sum test. Despite the measurement of tooth sensitivity
using VAS giving a continuous outcome, data assessed with this scale did not show a normal
distribution (Shapiro-Wilk's test). Thus, data from VAS will be also analyzed by the
Mann-Whitney rank sum test, while one test per time of evaluation will be carried out.
For color evaluation, comparisons between the sequences of treatment will be performed using
the Mann-Whitney rank sum test. The Friedman test followed by Dunn's post hoc test will be
used to analyze the difference between the moments of evaluation for each sequence of
treatment. All statistical analyses will be performed adjusting the initial significance
level (α = 0.05) by Bonferroni correction.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05865275 -
Diode Low-power Laser Before In-office Bleaching
|
N/A | |
Completed |
NCT03026725 -
Effect of Tri Calcium Phosphate on Efficacy and Sensitivity With Vital Tooth Whitening Using 20% Carbamide Peroxide
|
N/A | |
Completed |
NCT02935114 -
IN-OFFICE TOOTH BLEACHING WITH 37% CARBAMIDE PEROXIDE
|
Phase 3 | |
Completed |
NCT05483062 -
Effectiveness of Toothpaste Containing the Active Ingredient of Galla Chinensis Extract on Treating Dentin Hypersensitivity
|
N/A | |
Completed |
NCT02476032 -
An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity
|
N/A | |
Completed |
NCT04855279 -
Prevention of Bleaching Induced Sensitivity
|
N/A | |
Completed |
NCT05635253 -
Influence of Polishing After Bleaching on Color Change and Enamel Morphology
|
N/A | |
Completed |
NCT06288776 -
Efficacy of Azadirachta Indica Based Herbal Mouthwash in Treating the Tooth Hypersensitivity
|
N/A | |
Completed |
NCT03323372 -
Different Concentrations of Potassium Nitrate in In-office Tooth Bleaching Sensitivity
|
Phase 2 | |
Terminated |
NCT01988337 -
Lesion Progression After Icon Treatment in Young Adults
|
N/A | |
Active, not recruiting |
NCT06394557 -
Evaluation of In-office Bleaching-induced Sensitivity With 2 or 7 Days Interval Between Sessions
|
N/A | |
Completed |
NCT03403088 -
Non-carious Cervical Lesions and Treatments
|
N/A | |
Recruiting |
NCT05835453 -
At-home Bleaching Using Clear Aligners
|
N/A | |
Completed |
NCT03089216 -
Combined Bleaching Technique: Efficacy and Tooth Sensitivity
|
Phase 4 |